Skip to main content
. 2017 Feb 2;8(11):18095–18105. doi: 10.18632/oncotarget.14994

Figure 4. Effects of 5-fluorouracil in Bax-containing (Bax+/+) and Bax-deficient (Bax−/−) HCT116 human colon carcinoma cells mediated by TRAIL.

Figure 4

Bax-containing (Bax+/+) and Bax-deficient (Bax−/−) HCT116 human colon carcinoma cells were pretreated with 5-fluorouracil (40 μM) for 12 h. After that, cells were treated with 200 ng/mL of TRAIL protein for an additional 2 h. A. Cells were harvested and analyzed by Western blotting to determine the expression levels of Bax; B. Cell morphology photographed under light microscope (×100); C. Cell viability determined with crystal violet assay; D. Bax, Ac-cas3 and Ac-cas8 expression levels determined by western blot analysis. β-actin was used as loading control. 5-Flu: 5-Fluorouracil; Ac-cas3: Activated caspase 3; Ac-cas8: Activated caspase 8; TRAIL: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand.